重组促红细胞生成素治疗骨髓代偿不足的自身免疫性溶血性贫血的前瞻性分析
该前瞻性单中心队列纳入47例基线网织红细胞和內源性促红细胞生成素不足的自身免疫性溶血性贫血患者,每周皮下注射促红素α 40000国际单位至血红蛋白>11 g/dL后减量。15天总缓解率55%,1个月74%,3个月74%,6个月80%,12个月91%,血红蛋白较基线显著升高(P<.001),输血需求从30%降至15天及之后<10%(P<.001),未发生促红素相关严重不良事件。
要点
- 47例骨髓代偿不足的自身免疫性溶血性贫血患者接受促红素α每周40000国际单位皮下注射。
- 总缓解率15天55%、1个月74%、3个月74%、6个月80%、12个月91%。
- 血红蛋白较基线中位升高分别为+1.4、+2.4、+3.4、+3.8、+4.4 g/dL(P<.001)。
核心结论
- 这些数据支持在骨髓代偿不足的自身免疫性溶血性贫血中,将重组促红细胞生成素作为标准免疫抑制治疗的附加治疗。
研究设计与样本
- 前瞻性单中心队列分析,纳入47例基线网织红细胞增多不足且内源性促红细胞生成素不足的自身免疫性溶血性贫血患者。
- 促红素α 40000国际单位每周皮下注射,直至血红蛋白>11 g/dL后逐渐减量。
- 试验注册号为NCT05931718。
主要发现
- 总缓解率15天为55%、1个月为74%、3个月为74%、6个月为80%、12个月为91%。
- 血红蛋白较基线至各后续时间点均显著升高(P<.001),中位升高分别为+1.4、+2.4、+3.4、+3.8、+4.4 g/dL。
- 输血需求从30%降至15天及之后<10%(P<.001)。
- 合并用药包括泼尼松或甲泼尼龙(N=40,入组前稳定>2周)、吗替麦考酚酯(N=1,入组前持续>3个月)和利妥昔单抗(N=7例冷凝集素病患者从第8天开始),未发现合并用药与促红素疗效之间的关联。
- 治疗总体安全,未发生促红素相关严重不良事件;与未接受促红素治疗的自身免疫性溶血性贫血人群比较,促红素在15天和1个月时对缓解率和血红蛋白升高显示出显著获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Up to 30% of patients with autoimmune hemolytic anemia (AIHA) show inadequate bone marrow (BM) compensatory response with inappropriately low levels of reticulocytes and endogenous erythropoietin. Ineffective BM compensation is associated with more severe anemia, transfusion need, and hospital admission, and treatment with recombinant erythropoietin (rEPO) may be beneficial. Here, we prospectively analyzed the efficacy and safety of rEPO in a single-center cohort of 47 patients with AIHA with inadequate reticulocytosis and endogenous erythropoietin at baseline. Epoetin alpha 40 000 international units per week were administered subcutaneously until hemoglobin (Hb) >11 g/dL and then tapered off. Overall response was 55% at 15 days, 74% at 1 month, 74% at 3 months, 80% at 6 months, and 91% at 12 months. Consistently, Hb values significantly increased from baseline to each subsequent time point (P<.001) with a median increase of +1.4, +2.4, +3.4, +3.8, and +4.4 g/dL, respectively. Transfusion needs reduced from 30% to <10% at 15 days and thereafter (P < .001). Concomitant medications included prednisone or methylprednisolone (N = 40, stable since >2 weeks from enrollment), mycophenolate mofetil (N = 1, ongoing since >3 months from enrollment), and rituximab (N = 7 patients with cold agglutinin disease from day 8). No association between concomitant medications and response to rEPO was found. Treatment was generally safe without rEPO-related severe adverse events. The comparison with an AIHA population not treated with rEPO showed a significant benefit of rEPO at 15 days and 1 month on response and Hb increase. These data support the use of rEPO as an add on to standard immunosuppression in AIHA with inadequate BM compensation. This trial was registered at www.clinicaltrials.gov as #NCT05931718.
引用
- Fattizzo B, Pedone GL, Brambilla C, et al. Recombinant erythropoietin in autoimmune hemolytic anemia with inadequate bone marrow response: a prospective analysis. Blood Adv. 2024. PMID: 38029356. doi:10.1182/bloodadvances.2023011798
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。